how long have semaglutides been studied Study Shows 85% Of Patients Stop GLP-1s For Obesity After 2 Years A Staggering Number of U.S.

Further work is needed to explore consequences of long-term use of these medications, ideal insulin deprescription protocols, and strategies to alternatively dose these medications around ongoing shortages

Key Coverage Facts Coverage varies significantly by plan even within the same insurer, different employer plans have different formularies Coverage varies by employer size: 16% of mid-size employers (200-999 workers), 30% of large employers (1,000-4,999), and 43% of very large employers (5,000+) cover GLP-1 medications for weight loss [1] More than 88% of patients with coverage face prior authorization or other restrictionsyour doctor must get approval before you can fill it Medicare Part D excludes weight loss drugs by federal statute (may cover for CV risk reduction indication) About a dozen state Medicaid programs cover GLP-1s for obesity, though policies are evolving [2] Coverage by Plan Type Already denied

Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound

Sogar der Hersteller von Ozempic schreibt in einem Informationsschreiben fr rztinnen und rzte vom Mrz 2023: Jedes andere Anwendungsgebiet, inklusive Gewichtsregulierung, stellt eine off-label Anwendung dar und kann aktuell die Verfgbarkeit von Ozempic fr Menschen mit Typ 2 Diabetes gefhrden. Auch das Bundesinstitut fr Arzneimittel und Medizinprodukte (BfArM) warnt ausdrcklich vor einem nicht indikationsbezogenen Einsatz von Ozempic und Trulicity

This is exactly why medical supervision matters

If a refrigerator is not available, unopened vials can be kept at room temperature, but only for a short time, usually up to 28 days